On January 30, 2020 Medivir AB (Nasdaq Stockholm: MVIR) reports that the MIV-818 patent portfolio has been reinforced by the issue of notices of allowance from the European Patent Office and the Japanese Patent Office for the MIV-818 composition-of-matter and liver cancer treatment claims (Press release, Medivir, JAN 30, 2020, View Source [SID1234553728]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Corresponding notices of allowance or patent grants have already been issued in USA, Australia, Indonesia, Israel, Philippines, Russia, Singapore and South Africa. Applications are pending in a large number of other countries in Asia and around the world. The patents will be in force until August 2035.

– "It is comforting that our lead program MIV-818 can lean on such a solid intellectual property platform", says Dr. Uli Hacksell, CEO of Medivir.

For further information, please contact:

Uli Hacksell, CEO, Medivir AB, phone: +46(0)8-5468-3100.

About MIV-818

MIV-818 is a pro-drug designed to selectively treat liver cancers and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug to benefit patients with HCC and other forms of liver cancer. A phase I study in patients with liver cancer is ongoing.